| Autor: |
Morgan HJ; European Cancer Stem Cell Research Institute, School of Biosciences., Rees E; European Cancer Stem Cell Research Institute, School of Biosciences., Lanfredini S; European Cancer Stem Cell Research Institute, School of Biosciences., Powell KA; European Cancer Stem Cell Research Institute, School of Biosciences., Gore J; European Cancer Stem Cell Research Institute, School of Biosciences., Gibbs A; European Cancer Stem Cell Research Institute, School of Biosciences., Lovatt C; European Cancer Stem Cell Research Institute, School of Biosciences., Davies GE; European Cancer Stem Cell Research Institute, School of Biosciences., Olivero C; European Cancer Stem Cell Research Institute, School of Biosciences., Shorning BY; European Cancer Stem Cell Research Institute, School of Biosciences., Tornillo G; European Cancer Stem Cell Research Institute, School of Biosciences., Tonks A; Department of Haematology, Division of Cancer & Genetics, School of Medicine, and., Darley R; Department of Haematology, Division of Cancer & Genetics, School of Medicine, and., Wang EC; Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom., Patel GK; European Cancer Stem Cell Research Institute, School of Biosciences. |
| Abstrakt: |
The basis of immune evasion, a hallmark of cancer, can differ even when cancers arise from one cell type such as in the human skin keratinocyte carcinomas: basal and squamous cell carcinoma. Here we showed that the basal cell carcinoma tumor-initiating cell surface protein CD200, through ectodomain shedding, was responsible for the near absence of NK cells within the basal cell carcinoma tumor microenvironment. In situ, CD200 underwent ectodomain shedding by metalloproteinases MMP3 and MMP11, which released biologically active soluble CD200 into the basal cell carcinoma microenvironment. CD200 bound its cognate receptor on NK cells to suppress MAPK pathway signaling that in turn blocked indirect (IFN-γ release) and direct cell killing. In addition, reduced ERK phosphorylation relinquished negative regulation of PPARγ-regulated gene transcription and led to membrane accumulation of the Fas/FADD death receptor and its ligand, FasL, which resulted in activation-induced apoptosis. Blocking CD200 inhibition of MAPK or PPARγ signaling restored NK cell survival and tumor cell killing, with relevance to many cancer types. Our results thus uncover a paradigm for CD200 as a potentially novel and targetable NK cell-specific immune checkpoint, which is responsible for NK cell-associated poor outcomes in many cancers. |
